Endocardial Radiofrequency Ablation Vs. Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis

Overview

Journal Front Surg

Specialty General Surgery

Date 2022 May 13

PMID 35558385

Authors

Tao Jiang

Bingyu Huang

Shengqi Huo

Lulu Monica Mageta

Junyi Guo

Jiagao Lv

Li Lin

Affiliations

Soon will be listed here.

Abstract

Background: Septal myectomy (SM) has been the gold standard therapy for most patients with hypertrophic obstructive cardiomyopathy (HOCM). Endocardial radiofrequency ablation of septal hypertrophy (ERASH) is a novel treatment for septal reduction. We aimed to assess the efficacy and safety between two treatment strategies.

Methods: We searched PubMed, Web of Science, Cochrane Library, and Embase databases to identify relevant studies published up to March 2021. Random-effect models were used to calculate standardized mean difference (SMD) and 95% confidence intervals (CIs) for resting left ventricular outflow tract gradient (LVOTG) and septal thickness.

Results: Twenty-five studies are included in this review, eighteen studies for SM and seven studies for ERASH. During follow-up, there were significant reductions of the mean resting LVOTG in adults (SM groups: SMD = -3.03, 95% CI [-3.62 to -2.44]; ERASH groups: SMD = -1.95, 95% CI [-2.45 to -1.45]) and children (SM groups: SMD = -2.67, 95% CI [-3.21 to -2.12]; ERASH groups: SMD= -2.37, 95% CI [-3.02 to -1.73]) after the septal reduction therapies. For adults, SM groups contributed to more obvious reduction than ERASH groups in interventricular septal thickness (SM groups: SMD = -1.82, 95% CI [-2.29 to -1.34]; ERASH groups: SMD = -0.43, 95% CI [-1.00 to 0.13]). The improvement of the New York Heart Association class was similar in the two groups (SM groups: 46.4%; ERASH groups: 46.7%). The periprocedural mortality in SM and ERASH were 1.1 and 1.8%, respectively.

Conclusions: This systematic review suggests that SM is superior to ERASH in the treatment of HOCM. But for the patients who are at risk for open cardiac surgeries or prefer a less invasive approach, ERASH might be an optional approach.

Citing Articles

Recent Clinical Updates of Hypertrophic Cardiomyopathy and Future Therapeutic Strategies.

Zhao M, He X, Min X, Yang H, Wu W, Zhong J Rev Cardiovasc Med. 2025; 26(2):25132.

PMID: 40026515 PMC: 11868910. DOI: 10.31083/RCM25132.

Radiofrequency Catheter Septal Ablation via a Trans-Atrial Septal Approach Guided by Intracardiac Echocardiography in Hypertrophic Obstructive Cardiomyopathy: One-Year Follow-Up.

Li X, Liu T, Cui B, Chen Y, Tang C, Wu G Rev Cardiovasc Med. 2024; 25(2):38.

PMID: 39077341 PMC: 11263162. DOI: 10.31083/j.rcm2502038.

Radiofrequency ablation in patients with obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis.

Canzi C, do Prado Junior E, Junior A, Rezende A, Botelho S, Santos L Am Heart J Plus. 2024; 24:100229.

PMID: 38560638 PMC: 10978412. DOI: 10.1016/j.ahjo.2022.100229.

A Narrative Review of Emerging Therapies for Hypertrophic Obstructive Cardiomyopathy.

Junior A, de Oliveira A, Maia T, Botelho S Curr Cardiol Rev. 2023; 19(4):e240323214927.

PMID: 36999417 PMC: 10494274. DOI: 10.2174/1573403X19666230324102828.

References

Schleihauf J, Cleuziou J, Pabst von Ohain J, Meierhofer C, Stern H, Shehu N . Clinical long-term outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in infants. Eur J Cardiothorac Surg. 2017; 53(3):538-544. DOI: 10.1093/ejcts/ezx369. View

Sigwart U . Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995; 346(8969):211-4. DOI: 10.1016/s0140-6736(95)91267-3. View

Maron B . Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018; 379(7):655-668. DOI: 10.1056/NEJMra1710575. View

Sterne J, Egger M . Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001; 54(10):1046-55. DOI: 10.1016/s0895-4356(01)00377-8. View

Nishimura R, Seggewiss H, Schaff H . Hypertrophic Obstructive Cardiomyopathy: Surgical Myectomy and Septal Ablation. Circ Res. 2017; 121(7):771-783. DOI: 10.1161/CIRCRESAHA.116.309348. View

Lapenna E, Nisi T, Ruggeri S, Trumello C, Del Forno B, Schiavi D . Edge-to-Edge Mitral Repair Associated With Septal Myectomy in Hypertrophic Obstructive Cardiomyopathy. Ann Thorac Surg. 2020; 110(3):783-789. DOI: 10.1016/j.athoracsur.2020.03.095. View

Shelke A, Menon R, Kapadiya A, Yalagudri S, Saggu D, Nair S . A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Indian Heart J. 2016; 68(5):618-623. PMC: 5079133. DOI: 10.1016/j.ihj.2016.02.007. View

Cooper R, Shahzad A, Hasleton J, Digiovanni J, Hall M, Todd D . Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound® technology to guide ablation. Europace. 2015; 18(1):113-20. DOI: 10.1093/europace/euv302. View

Veselka J, Anavekar N, Charron P . Hypertrophic obstructive cardiomyopathy. Lancet. 2016; 389(10075):1253-1267. DOI: 10.1016/S0140-6736(16)31321-6. View

10.

Yao L, Li L, Lu X, Miao Y, Kang X, Duan F . Long-term clinical and echocardiographic outcomes of extensive septal myectomy for hypertrophic obstructive cardiomyopathy in Chinese patients. Cardiovasc Ultrasound. 2016; 14(1):18. PMC: 4869192. DOI: 10.1186/s12947-016-0060-9. View

11.

Altarabsheh S, Dearani J, Burkhart H, Schaff H, Deo S, Eidem B . Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in children and young adults. Ann Thorac Surg. 2012; 95(2):663-9. DOI: 10.1016/j.athoracsur.2012.08.011. View

12.

Porter K, Willis A, Zank J, Wild S . Phosphine-stabilized arsenium salts: water-stable, labile, coordination complexes. Inorg Chem. 2002; 41(24):6380-6. DOI: 10.1021/ic020410j. View

13.

Luo D, Wan X, Liu J, Tong T . Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2016; 27(6):1785-1805. DOI: 10.1177/0962280216669183. View

14.

Budde T, Breithardt G, Borggrefe M, Podczeck A, Langwasser J . [Initial experiences with high-frequency electric ablation of the AV conduction system in the human]. Z Kardiol. 1987; 76(4):204-10. View

15.

Zuo L, Hsi D, Zhang L, Zhang Q, Shao H, Liu B . Electrocardiographic QRS voltage amplitude improvement by intramyocardial radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy and one year follow up. J Electrocardiol. 2020; 61:164-169. DOI: 10.1016/j.jelectrocard.2020.06.013. View

16.

Wigle E, Sasson Z, Henderson M, Ruddy T, FULOP J, Rakowski H . Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis. 1985; 28(1):1-83. DOI: 10.1016/0033-0620(85)90024-6. View

17.

Crossen K, Jones M, Erikson C . Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy. Heart Rhythm. 2016; 13(9):1885-90. DOI: 10.1016/j.hrthm.2016.04.018. View

18.

Zhu C, Wang S, Ma Y, Wang S, Zhou Z, Song Y . Childhood Hypertrophic Obstructive Cardiomyopathy and Its Relevant Surgical Outcome. Ann Thorac Surg. 2019; 110(1):207-213. DOI: 10.1016/j.athoracsur.2019.10.016. View

19.

Wan X, Wang W, Liu J, Tong T . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. PMC: 4383202. DOI: 10.1186/1471-2288-14-135. View

20.

Afanasyev A, Bogachev-Prokophiev A, Ovcharov M, Pivkin A, Zalesov A, Budagaev S . Single-Centre Experience of Surgical Myectomy for Hypertrophic Obstructive Cardiomyopathy. Heart Lung Circ. 2019; 29(6):949-955. DOI: 10.1016/j.hlc.2019.07.009. View